UroGen invests $7M in IntraGel Therapeutics

A depot designed to deliver treatment locally

IntraGel’s SRGel is a biodegradable, solvent-free formulation that releases therapeutic agents gradually at the treatment site. TumoCure combines the gel with cisplatin for direct injection into solid tumors, aiming to sustain local drug exposure while limiting systemic effects; the company is advancing the approach through clinical development.

Use of funds

Advance SRGel platform

Accelerate clinical development of TumoCure

Funding history

Sep 1, 2026Strategic investment · This round$7M

Sources

IntraGel Therapeutics Receives $7M Investment From UroGen Pharmafinsmes.com · Sep 1, 2026

Similar rounds

All Biotech rounds →

Aventix

Aventix builds sensor-based analytical instruments for laboratories. Its first product, Scarlett 01, measures liquid volumes across microplate wells without touching the sample, helping R&D teams check dispensing quality and catch volume variation before it affects assay results.

€1.2MPre-seed · Sep 30, 2026

AnaCardio

AnaCardio is a clinical-stage biopharmaceutical company developing medicines intended to improve heart muscle function in people with heart failure.

€62.5MSeries B · Sep 30, 2026

Aptadir Therapeutics

RNA therapeutics designed to restore expression of silenced genes

€40MSeed · Sep 29, 2026

MOYOM Biotech

Develops absorbable biomaterials and implantable medical devices for regenerative aesthetic treatments.

UndisclosedFinancing round · Sep 28, 2026